Discontinued Operations Sale of Infusionz to Bloomios (Table)

12 Months Ended

Jun. 30, 2023

Discontinued Operations - Sale of Infusionz to Bloomios

Schedule Of inventory or working capital

Tangible assets, inventory / working capital*	$	(1,344,000	)
Tangible assets, warehouse and manufacturing equipment, net of accumulated depreciation*		(679,327	)
Goodwill		(2,413,814	)
Intangible assets, net of accumulated amortization		(946,996	)
Accrued and incurred expenses related to the transaction and additional working capital*		(2,051,500	)
Consideration received, including cash, debt and equity, net		15,000,000
Total gain recognized	$	7,564,363

Schedule Of Sale of Infusionz to Bloomios

Advance for payroll	$	50,000
Operating expense		652,891
Management fees		685,600
Excess working capital		388,565
Accrued Interest		247,885
Subtotal due from Bloomios	$	2,024,941
Reserve		1,179,498
Total due from Bloomios	$	845,443

Schedule Of Investments - Bloomios

Senior secured convertible debenture, net of unamortized original issue discount	$	5,218,209
Series D convertible preferred stock		8,500,000
Convertible Secured Subordinate Promissory Note		5,000,000
Reserve on Investments - Bloomios		(18,718,209	)
Total Investments - Bloomios	$	-

Schedule Of Discontinued Operations

	Year ended June 30,
	2023			2022
Discontinued Operations
Revenue	$	3,042,878		$	19,327,469
Cost of sales	$	1,803,643		$	10,743,028
Sales, general and administrative expenses	$	1,300,102		$	1,850,010
Depreciation and amortization	$	10,576		$	726,195
Income (loss) from discontinued operations, net of tax	$	(338,418	)	$	4,983,781
Accounts receivable net of allowance for doubtful accounts	$	-		$	941,465
Fixed assets, net of accumulated depreciation	$	-		$	670,528
Total assets	$	-		$	8,330,573
Total liabilities	$	-		$	167,008